175 related articles for article (PubMed ID: 15998901)
1. Neoadjuvant endocrine therapy for breast cancer: more questions than answers.
Ellis MJ
J Clin Oncol; 2005 Aug; 23(22):4842-4. PubMed ID: 15998901
[No Abstract] [Full Text] [Related]
2. Neoadjuvant endocrine therapy in breast cancer.
Abrial C; Mouret-Reynier MA; Curé H; Feillel V; Leheurteur M; Lemery S; Le Bouëdec G; Durando X; Dauplat J; Chollet P
Breast; 2006 Feb; 15(1):9-19. PubMed ID: 16230013
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
Smith IE; Dowsett M; Ebbs SR; Dixon JM; Skene A; Blohmer JU; Ashley SE; Francis S; Boeddinghaus I; Walsh G;
J Clin Oncol; 2005 Aug; 23(22):5108-16. PubMed ID: 15998903
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant use of endocrine therapy in breast cancer.
Macaskill EJ; Dixon JM
Breast J; 2007; 13(3):243-50. PubMed ID: 17461898
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant endocrine therapy in breast cancer.
Beresford MJ; Ravichandran D; Makris A
Cancer Treat Rev; 2007 Feb; 33(1):48-57. PubMed ID: 17134840
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen for breast cancer.
Karn A; Jha AK; Shrestha S; Acharya B; Poudel S; Bhandari RB
JNMA J Nepal Med Assoc; 2010; 49(177):62-7. PubMed ID: 21180225
[TBL] [Abstract][Full Text] [Related]
7. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
8. Aromatase inhibitors as adjuvant therapy for breast cancer: overall survival versus disease-free survival as a primary end point in clinical practice.
Sánchez-Muñoz A; Ribelles N; Márquez A; Pérez-Ruiz E; Alba E
J Clin Oncol; 2009 Dec; 27(35):e255-6; author reply e257-8. PubMed ID: 19884520
[No Abstract] [Full Text] [Related]
9. [Neoadjuvant antihormonal treatment of women with breast cancer].
Tuxen MK; Kamby C; Nielsen DL
Ugeskr Laeger; 2007 Sep; 169(37):3077-81. PubMed ID: 17877952
[TBL] [Abstract][Full Text] [Related]
10. Sequential or concurrent tamoxifen and radiotherapy: to see or not to see--that is the question!
Bentzen SM; Yarnold JR
J Clin Oncol; 2005 Sep; 23(25):6266-7; author reply 6267. PubMed ID: 16135499
[No Abstract] [Full Text] [Related]
11. Primary endocrine therapy in locally advanced breast cancers--the Nottingham experience.
Mathew J; Agrawal A; Asgeirsson KS; Buhari SA; Jackson LR; Cheung KL; Robertson JF
Breast Cancer Res Treat; 2009 Jan; 113(2):403-7. PubMed ID: 18311583
[TBL] [Abstract][Full Text] [Related]
12. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
Tuxen MK; Nielsen DL; Lindberg H; Kamby C
Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
[TBL] [Abstract][Full Text] [Related]
13. [Future endocrine therapy of breast cancer].
Ejlertsen B
Ugeskr Laeger; 2007 Jan; 169(4):296. PubMed ID: 17274921
[No Abstract] [Full Text] [Related]
14. Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials.
Tao Y; Klause A; Vickers A; Bae K; Ellis M
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):91-5. PubMed ID: 15994076
[TBL] [Abstract][Full Text] [Related]
15. Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer.
Dowsett M; Smith IE; Ebbs SR; Dixon JM; Skene A; Griffith C; Boeddinghaus I; Salter J; Detre S; Hills M; Ashley S; Francis S; Walsh G; A'Hern R
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1024s-1030s. PubMed ID: 16467120
[TBL] [Abstract][Full Text] [Related]
16. [Is low-dose tamoxifen an effective therapy for breast carcinoma in situ?].
Ivanova OA; Zhil'tsova EK; Barash NIu; Ivanov VG; Ermachenkova AM
Vopr Onkol; 2011; 57(5):601-3. PubMed ID: 22238929
[No Abstract] [Full Text] [Related]
17. The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer.
Banerjee S; Pancholi S; A'hern R; Ghazoui Z; Smith IE; Dowsett M; Martin LA
Clin Cancer Res; 2008 May; 14(9):2656-63. PubMed ID: 18451229
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer (non-metastatic).
Dixon JM; Rodger A; Stebbing J
Clin Evid; 2005 Jun; (13):2226-57. PubMed ID: 16135326
[No Abstract] [Full Text] [Related]
19. Adherence to endocrine therapy for breast cancer.
Chlebowski RT; Geller ML
Oncology; 2006; 71(1-2):1-9. PubMed ID: 17344666
[TBL] [Abstract][Full Text] [Related]
20. Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?
Tang SC
Cancer Invest; 2008 Jun; 26(5):481-90. PubMed ID: 18568770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
